M3 Inc (JP:2413)
:2413
Want to see JP:2413 full AI Analyst Report?
Top Page
M3
(2413)
Select Model
Select Model
Rating:68Neutral
Price Target:
¥1,432.00
▼(-33.61% Downside)
Action:Downgraded
Date:05/03/26
The score is driven primarily by strong financial quality (low leverage, solid profitability, improving growth, and robust free cash flow). This is partially offset by clearly weak technical conditions (below major moving averages with negative momentum indicators) and only moderately supportive valuation (P/E ~18.9; ~1.47% yield).
Positive Factors
Conservative Balance Sheet
Extremely low leverage and steady equity growth give M3 durable financial flexibility. This conservatism lowers refinancing and liquidity risk, supports investment or M&A optionality, and enables the company to sustain operations and shareholder returns through economic cycles.
Negative Factors
Margin Compression
Eroding margins suggest rising costs or a less favorable service mix, which can pressure long-term profitability even if revenue grows. Sustained margin compression would reduce free cash flow and constrain the company’s ability to invest in product development or expand high-return initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Extremely low leverage and steady equity growth give M3 durable financial flexibility. This conservatism lowers refinancing and liquidity risk, supports investment or M&A optionality, and enables the company to sustain operations and shareholder returns through economic cycles.
Read all positive factors
M3 (2413) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.08T
Dividend Yield1.01%
Average Volume (3M)2.99M
Price to Earnings (P/E)21.7
Beta (1Y)0.79
Revenue Growth23.33%
EPS Growth21.65%
CountryJP
Employees12,100
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)60.49
Shares Outstanding679,124,300
10 Day Avg. Volume2,689,370
30 Day Avg. Volume2,988,500
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)2.66
Price to Sales (P/S)3.09
P/FCF Ratio17.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,241.25Price Target Upside3.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)82.2
Revenue Forecast (FY)¥392.07B
M3 Business Overview & Revenue Model
Company Description
M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates through five reporting segments: Medical Platform, Evidence Solution, Career Solution, Site Solution, and ...
How the Company Makes Money
M3 makes money by operating healthcare and life-sciences platforms and selling services to both healthcare professionals (via platform offerings) and, more significantly, to enterprise customers such as pharmaceutical and medical device companies ...
M3 Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 306.89B | 351.36B | 284.90B | 238.88B | 230.82B | 208.16B |
| Gross Profit | 161.71B | 175.84B | 154.36B | 140.53B | 135.19B | 123.27B |
| EBITDA | 78.87B | 87.33B | 77.71B | 78.11B | 81.82B | 102.51B |
| Net Income | 41.08B | 49.10B | 40.48B | 45.27B | 49.03B | 63.84B |
Balance Sheet | ||||||
| Total Assets | 584.60B | 637.40B | 581.74B | 490.78B | 400.64B | 345.98B |
| Cash, Cash Equivalents and Short-Term Investments | 102.14B | 156.18B | 166.75B | 179.74B | 146.25B | 141.12B |
| Total Debt | 26.14B | 33.15B | 51.42B | 31.78B | 10.38B | 8.30B |
| Total Liabilities | 175.49B | 190.75B | 168.94B | 124.08B | 91.13B | 82.03B |
| Stockholders Equity | 374.30B | 408.22B | 378.44B | 351.92B | 302.63B | 257.84B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 62.58B | 45.45B | 52.90B | 51.20B | 50.40B |
| Operating Cash Flow | 0.00 | 70.26B | 51.74B | 58.31B | 57.11B | 52.11B |
| Investing Cash Flow | 0.00 | -15.89B | -39.15B | -29.31B | -27.52B | -26.82B |
| Financing Cash Flow | 0.00 | -35.47B | -27.16B | -712.00M | -17.25B | -12.96B |
M3 Technical Analysis
Neutral
2157.00
Price Trends
1507.98
Positive
1639.41
Negative
1939.27
Negative
Market Momentum
14.37
Negative
65.88
Neutral
89.86
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2413, the sentiment is Neutral. The current price of 2157 is above the 20-day moving average (MA) of 1421.75, above the 50-day MA of 1507.98, and above the 200-day MA of 1939.27, indicating a neutral trend. The MACD of 14.37 indicates Negative momentum. The RSI at 65.88 is Neutral, neither overbought nor oversold. The STOCH value of 89.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2413.
M3 Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥1.08T | 21.71 | 12.15% | 1.01% | 23.33% | 21.65% | |
60 Neutral | ¥180.55B | 26.68 | ― | 0.43% | 20.95% | 13.39% | |
54 Neutral | ¥10.19B | 35.92 | ― | 5.30% | 15.59% | -80.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥71.99B | 67.53 | 5.76% | ― | 23.30% | -56.05% | |
43 Neutral | ¥2.43B | -4.57 | ― | ― | 18.86% | 38.80% |
* Healthcare Sector Average
JP:2413
M3
1,590.00
-470.52
-22.84%
JP:4480
Medley
2,199.00
-801.00
-26.70%
JP:4438
Welby Inc.
288.00
-67.00
-18.87%
JP:4483
JMDC Inc.
2,759.00
-917.12
-24.95%
JP:9341
GENOVA Inc.
571.00
-120.72
-17.45%
M3 Corporate Events
M3 Issues Investor Presentation With Caution on Projections
May 1, 2026
M3, Inc. has released a presentation outlining forecasts, plans, management targets, and other projections for the company and its group based on currently available data. The company emphasizes that these projections may differ from actual result...
M3 Launches Up to ¥20 Billion Share Buyback to Bolster Capital Efficiency
May 1, 2026
M3, Inc. has approved a share repurchase program of up to 20 million common shares, representing about 3.00% of outstanding stock, for a total consideration of up to 20 billion yen. The buyback, to be executed via open-market purchases on the Toky...
M3 Lifts Profit 21% and Hikes Dividend as It Targets Further Growth in FY2027
May 1, 2026
M3 reported strong results for the fiscal year ended March 31, 2026, with revenue climbing 23.3% to ¥351.4 billion and profit attributable to owners of the parent rising 21.3% to ¥49.1 billion. Operating cash flow improved to ¥70.3 ...
M3 Completes ¥20 Billion Share Buyback, Tightening Free Float
Mar 16, 2026
M3, Inc. has completed a share repurchase program authorized by its board, buying back 3,911,900 common shares for about ¥6.44 billion between March 1 and March 13, 2026, via open market purchases on the Tokyo Stock Exchange. Under the broade...
M3 Advances Share Buyback, Acquires 5.8 Million Shares in February
Mar 2, 2026
M3, Inc. reported progress on its ongoing share repurchase program authorized by its board in May 2025 under Article 459 of the Companies Act, aimed at buying back up to 20 million common shares for as much as 20 billion yen. Between February 1 an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.